Armata Pharma CMO Mina Pastagia departs; separation agreement provides 12-month salary continuation

Armata Pharmaceuticals, Inc.

Dr. Mina Pastagia terminated as Chief Medical Officer effective Nov 13, 2024; separation agreement executed Dec 2, 2024.
Agreement provides 12 months of base salary continuation, paid in equal installments starting ~60 days post-termination.
All unvested stock options and restricted stock units forfeited; vested options must be exercised within 90 days of separation.
Pastagia releases all claims against the company in exchange for the severance benefits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.